Today's guest is Emma Vitalini, Head of Global Digital Health Technology Innovation at Amgen. Amgen is a global biotechnology company focused on discovering, developing, and delivering medicines for serious illnesses. Emma joins Emerj Editorial Director Matthew DeMello to examine how data and AI are reshaping patient recruitment, decentralized clinical trials, and compliance workflows in highly regulated healthcare environments. Emma also discusses practical ways AI can surface unstructured genomic and clinical data to improve patient identification, how API-based access supports hypothesis testing without large-scale data movement, and how modular consent and explainable AI frameworks help sponsors scale trial operations while maintaining regulatory trust and patient transparency. Learn how brands work with Emerj and other Emerj Media options at go.emerj.com/partner

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related